Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Alternative Names: AR 13154; AR-101; AR-13165; AR-13533; AR-202

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Janus kinase inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Platelet-derived growth factor beta receptor antagonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy; Dry age-related macular degeneration; Neurological disorders; Wet age-related macular degeneration
  • No development reported Glaucoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic)
  • 05 Oct 2017 Aerie Pharmaceuticals in-licenses PRINT® technology from Envisia Therapeutics
  • 05 Oct 2017 Preclinical trials in Diabetic retinopathy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top